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Few advances in medical research have generated 
as much interest and controversy as those relating 
to stem cell research and its potential applications 
in cell and gene therapy, regenerative medicine and 
tissue engineering. Recent techniques involving induced pluripotent 
stem cells (iPSCs) and human somatic cell nuclear transfer (SCNT) 
have raised new ethical and legal questions. The predominant early 
focus on an ‘embryo-centric’ approach in this field is slowly being 
overtaken by an approach focused on the globalisation of research 
and a concomitant need for ‘policy interoperability’.[1]
Globally, policies and legislation regulating these developments are 
complex and varied, both within and between jurisdictions, described 
by some authors as ‘a patchwork of patchworks’.[2] In addition to 
variation in national laws and policies with regard to biomedical 
research and the development of therapeutic applications, variation 
also exists with regard to other related activities, such as research 
funding, normative and ethical principles and standards, governance 
mechanisms, quality assurance and access to stem cell material and 
data.[3] The regulatory environment is also deeply influenced by social, 
religious, cultural, economic, historical, ideological and political 
factors. Competing interests and values promoted and propagated by 
various agents from, among others, the scientific community, political 
parties, consumer organisations, interest groups (patient groups, 
religious organisations and pro-life organisations), the media and the 
general public, are also relevant.[4] Moral perceptions regarding the 
human embryo have shaped and informed substantive requirements 
and procedural safeguards regarding the use of human embryonic 
stem cells (hESCs) in many jurisdictions.[5]
National policy development in this field is guided by international 
and regional instruments, guidelines and regulations that span 
biomedical research and related activities, adding a further layer of 
complexity. The United Nations Educational, Scientific and Cultural 
Organisation (UNESCO), Council of Europe and the EU have all 
addressed aspects of stem cell research and its clinical applications 
through various reports, treaties, resolutions, declarations and 
guidelines. Guidelines and recommendations by international 
organisations, such as the Council for International Organisations 
of Medical Science (CIOMS), the Hinxton Group, the International 
Consortium of Stem Cell Networks (ICSCN), the International Stem 
Cell Forum (ISCF) and the International Society for Stem Cell Research 
(ISSCR) are an instructive resource for policymakers. Nonetheless, 
human stem cell research, which involves the embryo and its clinical 
translation, remains a matter for national policy and lawmakers.
The impact of conflicting regulatory regimens is manifold and 
may affect, among others, the conduct of research, efficiency, 
collaboration, the clinical translation and commercialisation[6] of 
research.[3] Although regulatory variation is a natural consequence of 
heterogeneous contexts, unintended and unforeseen consequences 
may arise in areas where there are legal regulatory lacunae. One 
example is the need to balance innovative therapies with rigorous 
oversight and regulation in the exploitation of vulnerable patients 
through unproven and potentially harmful stem cell treatments 
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in jurisdictions where the regulatory frameworks are ineffective or 
ambiguous.[7] The most common response to policy variance is a call 
for the development of harmonised legal and ethical standards.[1]
A clearer understanding of the comparative global regulatory 
framework will assist in determining the scope of policy 
convergence or consistency that is required in order to navigate 
more efficient and ethical research and research collaboration in 
this field, as well as identify strategies to address these differences 
that may impede scientific progress and innovation.[2] It will 
also enable specific areas in the field to be harmonised, which 
could lead to improved policy interoperability.[2] Improved policy 
interoperability is possible when harmonisation of regulatory 
approaches is the focus (which doesn’t require similarity but rather 
compatibility),[8] instead of standardisation (which focuses on 
uniformity of approaches).[1]
The purpose of this article is hence to explore the international legal 
regulatory framework by comparing selected national approaches 
toward human stem cell research and therapy by focusing on 
restrictions or permissions with regard to specific research activities. 
The different national approaches are best understood in terms of a 
continuum with the most liberal and permissive regulatory regimens 
at one end (e.g. those that permit embryo research and the derivation 
of hESC from various sources and technologies, such as SCNT) and 
those that prohibit embryo research and related activities (e.g. the 
use of excess IVF embryos in hESC research) at the other. Surprisingly, 
jurisdictions with common political, legal, cultural and religious 
contexts may have very different policy approaches with regard to 
hESC research.[2]  
On a global front, the development of therapeutic stem cell 
applications, similar to that of stem cell research, is likewise 
characterised by legal uncertainty, and regulatory frameworks 
are under revision to cater for the unique challenges posed by 
translational stem cell research, which include efforts to harmonise 
guidelines relating to safety, efficacy, quality and the development of 
common technical requirements.
The comparisons drawn in this paper will assist in guiding future 
legislative developments in the fields of stem cell research and its 
clinical translation in South Africa. 
Ethical issues
Moral status of human embryo
The moral and legal status of the human embryo has always 
been clouded in controversy. A recent study that explored public 
perceptions regarding the moral status of the human embryo in 
nine European countries is no exception. Statements describing the 
embryo as a cluster of cells (e.g. the relative majority view in Denmark 
and the UK) were contrasted to others that accord the human embryo 
the same moral status as other human beings (more prevalent in 
Austria, Germany, Poland, and Italy).[9]
Moral views on the human embryo are informed by the specific 
significance that persons attach to different stages of human 
embryonic development [10] such as fertilisation, when the primitive 
streak develops, when the fetal heart begins to beat, when mental 
functioning of the fetus commences, when the fetus becomes viable 
outside the womb, sustained with the help of technology, or when 
the child is born and able to breathe independently.[11] These moral 
perceptions may explicitly or implicitly influence views regarding 
the possible uses and creation of human embryos for research 
purposes, and ultimately reflect society’s understanding of, trust in 
and expectations and reservations regarding scientific advances in 
this field. These important embryonic developmental milestones may 
perhaps not be useful in answering the question of when the law 
should recognise the embryo or fetus as a legal person to whom the 
full panoply of civil or constitutional rights should apply, but become 
relevant when demarcation lines are drawn for research activities 
involving the human embryo. For example, many jurisdictions agree 
on a 14-day limit following fertilisation, after which embryos may not 
be permitted to develop further in vitro.[10] An embryo beyond 14 
days’ development is unlikely to implant in a woman’s womb.
The ambivalence regarding the embryo is reflected in an array 
of definitions across jurisdictions, with some defining the human 
embryo in relation to a specific time of embryonic development 
(e.g. eight weeks from the moment of conception, e.g. South 
Africa,[12] Australia,[13] India[14] and Singapore[15]), others stating its 
definitions in broad time frames (e.g. a ‘fertilised ovum at all stages 
of development’, e.g. Iceland, Estonia, UK, Finland and South 
Korea), and those that avoid references to gestational development, 
focusing instead on the capacity of the embryo to develop into a 
human being (e.g. New Zealand, Belgium, Japan and Germany).[16] 
In a ruling on 18 December 2014,[17] the Court of Justice of the EU 
clarified the status of embryos created through parthenogenesis 
(having only one set of DNA and unable to develop into human 
beings) by confirming that these parthenotes are excluded from 
the definition of a ‘human embryo’ as contained in Directive 98/44/
EC of 6 July 1999 of the European Parliament and Council on the 
legal protection of biotechnological inventions, and are hence 
patentable.[18]
The hESC research has been regarded as ethically controversial 
by many because it is associated with the destruction of the human 
embryo i.e. when pluripotent stem cell lines are derived from the 
inner cell mass (ICM) of the 5 to 7-day-old pre-embryo or blastocyst. 
The issue at stake, referred to above, is whether the embryo is merely 
a clump of cells or whether its (developmental) potential to become 
a human being bestows on it all the qualities and characteristics 
associated with human personhood (and consequently legal 
protection as a legal subject). The answers to these questions will 
determine the limits on the research activities that may be morally 
(and legally) permitted with regard to human embryos. Secondly, 
the source of these human embryos or hESCs is also relevant. 
For example, in the case of embryos, were they created solely for 
research purposes or were they excess embryos left over after in vitro 
fertilisation? If not used and destined to be discarded in any event, 
would it be morally justifiable to use them in medical research aimed 
at ultimately benefiting the greater collective? Many jurisdictions 
insist on the destruction of human embryos used for research 
purposes, before 14 days of development (time at which the primitive 
streak appears).
The human embryo is not the only source of pluripotent stem 
cells. Pluripotent stem cells can also be derived from oocytes using 
specific techniques, such as SCNT. However, this process also requires 
development to the blastocyst phase in order to harvest ICM cells 
for creating ES cells. With regard to oocyte donation for research, 
this carries specific medical risks when the oocytes are retrieved. In 
addition, ethical concerns arise relating to the donation of oocytes 
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for research, as well as human reproduction and the protection 
of the reproductive interests of women undergoing infertility 
treatment.[19] Compliance with research governance requirements, 
informed consent procedures, as well as issues revolving around 
reimbursement or payment of gamete or embryo donors, is a key 
ethical consideration.[8]
Reproductive and therapeutic cloning
The creation of stem cells through SCNT is another contested issue. 
This procedure, which entails the removal of nuclear DNA from an 
unfertilised oocyte and replacing the removed DNA with the nuclear 
DNA from a somatic donor cell, was successfully carried out for the 
first time using human cells in 2013.[20] The reprogrammed oocyte 
containing the replaced DNA (genetically identical to the DNA of 
the donor) is stimulated to divide and develop into a blastocyst 
from which hESCs are harvested to create a stem cell line genetically 
identical to that of the cell donor. This technique allows researchers 
to develop genetically identical or compatible tissue for successful 
autologous tissue transplantation procedures. SCNT is controversial 
for two reasons. First, the harvesting of ICM cells from the blastocyst 
to create ES cells, and second because it may lead on to ‘cloning’ or 
the reproduction of a genetically identical organism. The intentional 
creation of embryos using this technique in humans (but not in 
domestic animals) is condemned for a number of reasons, namely 
that it diminishes human individuality and integrity, impacts on 
the freedom, identity and dignity of the human person (in the 
sense that multiple identical copies of the same DNA are possible), 
as well as human reproductive autonomy (e.g. that an embryo is 
created with only one genetic parent to which the embryo would be 
asymmetrically and genetically identical). Cloning furthermore raises 
the prospect of eugenics, for example the creation of offspring with 
certain desired and genetically enhanced characteristics, which will 
take society beyond therapy into very dangerous and unchartered 
terrain. These concerns raise vexing questions that are fundamental 
to our understanding of humanity, human identity, and inviolability 
of the human person, human reproduction and human dignity. 
Strong opposition globally to cloning led to a world-wide ban on 
reproductive cloning in humans,[21] and as a consequence has cast 
a shadow on the use of SCNT, without distinguishing between 
‘therapeutic cloning’ and ‘reproductive cloning’.  As a technique, SCNT 
may produce a cloned embryo, but the purpose of the process (e.g. 
research, therapy or reproduction) is a separate matter. 
There is also some misunderstanding regarding the difference 
between ‘therapeutic cloning’ and ‘reproductive cloning’. The first-
mentioned is aimed at using the ES cells derived from SCNT in 
experiments focused on understanding disease and developing 
treatments for disease and not at creating a living (cloned) baby, 
as would be the goal of the latter. To date, no conclusive evidence 
exists that a human being has ever been cloned successfully, despite 
numerous claims in this regard over the past decade.[22]
Oocyte donation
Carrying out SCNT requires oocytes, which have to come from female 
egg donors. Donating oocytes through hyper-ovulation is an invasive, 
time-consuming and painful process. Altruistic oocyte donation is 
therefore less common than sperm donation. For this reason, and to 
counter the demand for oocytes, it has been suggested that women 
donating oocytes receive, in addition to the conventional ‘out-of-
pocket expenses’, fair compensation for physical discomfort, subject 
to strict ethical guidelines.[23] The South Korean Woo Suk Hwang 
scandal in 2006 best illustrates some of the more serious ethical risks 
associated with oocyte donation, namely inappropriate payment to 
oocyte donors (laboratory staff), undue influence on these female 
employees to donate oocytes, as well as a high incidence of medical 
complications following the oocyte donation.[24]
Fetal tissue that becomes available after abortion is another source 
of pluripotent stem cells. Apart from the moral issues relating to the 
source of these cells, i.e. abortion, the donation of this type of tissue is 
generally only permitted after the decision to terminate a pregnancy 
has been made.[19]
Induced pluripotent stem cells
Induced pluripotent stem cells refer to somatic cells that can be 
reprogrammed to form pluripotent cells. As the reprogramming 
of these cells does not involve human embryos or oocytes, iPSCs 
are generally regarded as ethically unproblematic, as the concerns 
outlined above are absent. Obtaining the somatic cells (e.g. through 
a skin biopsy) is considered to be non-invasive when compared 
to the donation of oocytes used in the SCNT procedure. Concerns 
related to the use of iPSCs include possible downstream uses of the 
iPSC derivates, which may include the genetic modification of cells, 
large scale genomic sequencing, the sharing of cell lines among 
researchers, the possibility of deriving gametes in vitro from iPSCs and 
the commercialisation of applications involving the cells.[19] Recent 
studies have demonstrated the potential of iPSCs to differentiate into 
both male and female germ cells in different species. One of these 
includes the development of functional gametes and offspring in 
mice.[25] This example raises complex legal and ethical issues relating 
to the sequence and process of reproduction and genetic parentage, 
not to mention informed consent issues, concerns regarding cloning, 
as well as the potential to create an embryo by donors that may be 
unaware of such a possibility or attempt.
Intellectual property issues
The question of intellectual property rights in the context of stem 
cell research is also fraught with ethical controversy, specifically 
concerning the patenting of living things or products of nature. In 
contrast to purified or isolated stem cells that are generally patentable 
as research tools, including the methods and reagents to grow and 
generate stem cell lines, there has been variance in legal approaches 
regarding the patenting of hESCs themselves (as living things) across 
jurisdictions, notably between Europe, the USA and Japan.[26] In 2008, 
the Expanded Appeal Board of the European Patent Office ruled that 
hESC lines for industrial or commercial purposes are not eligible for 
patent protection in Europe.[27] This ruling (in sharp contrast to the 
position in the USA) was followed by a ruling of the European Court 
of Justice in 2011 that banned patents on procedures involving the 
destruction of human embryos at any stage, including procedures 
used for the creation of hESC lines, as well as those using previously 
derived cell lines.[28]
Intellectual property issues touch on a legal conundrum regarding 
the right of donors to retain property or proprietary interests in 
their own tissues, embryos or genetic material. The most commonly 
accepted view rejects property claims of research participants to 
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biological material that they donated to research, despite the fact 
that their samples may lead to very profitable cell-line applications 
in which they will not share.[29] This may appear inequitable and 
conflicting if one considers the continuing rights of donors regarding 
the uses and secondary uses involving their tissue samples. On the 
other hand, property rights in embryos were (implicitly or explicitly) 
recognised by courts in the USA,[30] and also in respect of stored 
gametes (the USA,[31] Australia[32] and the UK[33]). 
Informed consent and other issues
More general ethical concerns relevant to the field of stem cell 
research and therapy are those relating to informed consent, 
specifically considering that cell lines may potentially be used 
indefinitely for future research not yet conceived. Questions arise as 
to the circumstances under which currently stored samples may be 
used for further stem cell research without consent, as well as the 
right of donors to withdraw their participation at any time during 
the research. Guideline documents on this issue differ, with some 
suggesting that donors can withdraw consent until the creation of 
an anonymised cell line,[34] and others until an embryo or blastocyst 
is used in the derivation of a cell line.[35] If donors may withdraw 
consent to participate in research once a cell line is created, this 
may drastically impact on further research. There is generally strong 
support for the right of withdrawal to endure.[36] Induced pluripotent 
stem cell research raises unique consent challenges that may require 
a specialised approach to consent (e.g. one that details common uses 
and possible uses of cell lines that donors may find problematical, for 
example producing human-animal chimeras and the derivation of 
human gametes).[37]
Protecting the privacy and confidentiality of donors of tissues, 
gametes or embryos in the context of stem cell research always 
remains a concern, specifically as far as the potential traceability of 
stem cell lines is concerned.[37] The issue of how to address incidental 
findings (i.e. that a donor suffers or is likely to suffer from a specific 
disease) is another concern.
Stem cell research: Regulatory 
approaches
With the permissibility and prohibition of specific activities as the 
yardstick for comparison, this section provides a broad global 
overview of distinctive legislative and policy approaches relating 
to stem cell research (Table 1). As noted earlier, these approaches 
reflect intricate and nuanced differences, which should be 
interpreted within the wider context of each jurisdiction’s legal, 
socio-economic, political and cultural tradition. In addition, the 
design of each regulatory framework may be influenced by specific 
or general statutory provisions or professional guidelines (as in India, 
for example) or by a combination of both.[16] All the jurisdictions 
listed below prohibit the reproductive cloning of human beings. The 
specific research activities involving embryos selected for comparison 
below are likewise not consistently and similarly articulated in the 
different legal and policy documents across these jurisdictions, with 
the result that in some instances, the permissibility or prohibition 
of these activities was deduced from more general proscriptions. 
For example, a prohibition on the creation of human embryos for 
research or therapeutic purposes would include a prohibition of the 
use of SCNT to create an embryo.
Issues, on which policy variances across these jurisdictions are most 
evident, are the moral (and legal) status of the human embryo, the 
patenting of human tissues and payment of tissue and gamete 
donors. On the other hand, consensus is more uniform on the issues 
of prohibition of reproductive cloning, research standards, clinical 
readiness, cell line quality and scientific integrity.[2] Matters related 
to stem cell therapy (as opposed to research) will be considered 
separately, since this is a separate debate with an additional set of 
parameters.
Liberal
At the one end of the spectrum are jurisdictions that permit a number 
of activities with regard to stem cell research, which include the 
creation and use of embryos and derivation of stem cell lines from 
various sources for a number of purposes. Liberal approaches, through 
tight regulations, generally permit SCNT under specific circumstances 
and are subject to procedural rules and governance mechanisms. 
The overall objective of the liberal frameworks is to advance scientific 
progress, while at the same time taking into account public concerns.
Jurisdictions belonging to this category are, for example, Australia, 
Belgium, India, Iran, Israel, Japan, Singapore, South Korea, South 
Africa, Spain, Sweden, Taiwan, the UK and selected states in the USA 
(e.g. California, Illinois, Iowa, Maryland and New Jersey).
Moderate
Jurisdictions adopting a moderate approach to stem cell 
research allow a measure of flexibility and typically permit a 
range of activities, subject to specific regulatory checks and 
balances. Jurisdictions belonging to this category attempt to 
strike a regulatory compromise between contradicting or diverse 
interests. Some of these jurisdictions permit research using surplus 
IVF embryos under specific circumstances, but may prohibit hESC 
derivation from other sources or involving specific techniques, 
such as embryos created using SCNT. The use of excess or surplus 
embryos is generally subject to conditions relating to informed 
consent of the donors, payment of donors and restrictions on the 
use of embryos beyond 14 days.
Countries whose stem cell regulatory frameworks may be 
considered moderate are, for example, Brazil, Canada, Denmark, 
Finland, France, Greece, the Netherlands, New Zealand, Norway, 
Slovenia, Switzerland, and some states in the USA (e.g. Arkansas, 
Montana, and Virginia).
Prohibitive
Jurisdictions characterised as having adopted a restrictive approach 
expressly prohibit the creation and use of embryos for research 
purposes or for the derivation of hESCs, or may allow the use of 
imported hESC lines under tightly controlled and limited conditions. 
Although some of these countries do not explicitly prohibit or ban 
therapeutic cloning, the creation of embryos for research purposes 
is prohibited, which implies curtailment of therapeutic cloning. The 
protection of human life and dignity in the contexts of eugenics and 
abortion is a specific legal concern in some of these jurisdictions (e.g. 
Germany and Ireland).
Countries that fall into this category are Austria, Costa Rica, 
Germany, Ireland, Italy, Lithuania and some states in the USA (e.g. 
Oklahoma).
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Table 1. Stem cell research: Regulatory approaches
Jurisdiction
*Legal position unclear, e.g. whether permitted 
or prohibited












of hESC lines 







hESCs, but permit 
importation of 
hESC lines






Costa Rica √ √
Denmark √ √
Finland * * √
France √ √

















South Africa √ √







(variation of laws within states)
No federal ban on hESC research, but restrictions on federal funding before 9 March 2009; federal 
funding only permitted for non-hESC research or those using hESC lines in existence prior to 9 
August 2001. President Obama’s Executive Order lifted these restrictions for research involving new 
hESC lines. No federal funding under 2009 NIH Guidelines for research  that creates human embryo 
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Stem cell therapy: Regulatory approaches
Introduction
The global regulation of stem cell therapies, similar to that of stem cell 
research, is characterised by legal uncertainty, with many jurisdictions 
revisiting regulatory systems to address the needs and challenges 
posed as cell and tissue therapies emerge. Effective global regulation 
is hampered by the diverse nature of stem cell-based products and 
that regulatory regimens differ with regard to the intended clinical 
use of the cell product, method of clinical delivery and manufacture.[38] 
The expansion of the harvested cells in vitro to generate a sufficient 
dose for therapeutic use, regarded as a more-than-minimally 
manipulated process, has added additional regulatory complexities, 
and products generated in this way are classified either as advanced 
therapy medicinal products (ATMPs) (the position in the EU) or 
biologics (the position in the USA).[9] Regulatory differences between 
the EU and the USA, for example, relate not only to the clinical trial 
requirements (e.g. the EU’s Clinical Trial Authorisation (CTA) and 
the Investigational New Drug application (IND) in the USA), but 
also to the data required to establish quality, safety and efficacy 
of cell therapies. Existing regulatory frameworks for the donation, 
procurement, processing and preservation of cells and tissues are 
often based on the so-called ‘conventional pharmaceutical paradigm’, 
which, considering the distinct features of stem cells, introduces 
obstacles with respect to the safety and efficacy of stem cell lines 
which are very different from other pharmaceutical products.[39] In 
addition, novel applications using hESCs or iPSCs may carry specific 
and unforeseen risks. 
We will focus on the regulatory regimens for stem cell-based 
products in the EU and the USA, as this comparison will best 
illustrate the regulatory challenges associated with stem cell-based 
applications. 
As this section will show, there is a need for greater harmonisation 
of regulatory standards and requirements across the world. One 
example is cell-device combinations, regulated as ATMPs in the EU 
but as medical devices in the USA, hence requiring different data from 
clinical trials in each of these instances. Current efforts to harmonise 
regulatory requirements include the International Conference on 
Harmonisation (ICH),[40] and a European Medicines Agency-Food and 
Drug Administration (EMA-FDA) joint committee. Other instructive 
non-binding codes of practice or guidelines, referred to above, are 
those published by international bodies, such as the ISSCR and the 
Hinxton Group.
European Union
Medicinal products based on human cells and tissues are classified 
(Table 2) as ATMPs in the EU (under Regulation (EC) 1394/2007) and 
can only be authorised for general use by the European Medicines 
Agency (EMA). The ATMP regulation enabled the European 
Commission to adopt specific requirements regarding issues such as 
good clinical practice, good manufacturing practices, the content of 
marketing authorisation applications, and the traceability of ATMPs.[41]
ATMPs include gene therapy medicinal products, somatic cell 
products and tissue-engineered products. Provision is also made 
for the establishment of a Committee on Advanced Therapies (CAT), 
which provides a central cell therapy product evaluation procedure 
and assesses the quality, safety and efficacy of ATMPs for the final 
approval by the Committee for the Medicinal Products for Human 
Use (CHMP).  Exempted from the ATMP regulations are products 
prepared on a ‘non-routine’ basis and used within the same member 
state in a hospital as prescribed for an individual patient.[42] This 
‘hospital exemption’ allows patients to receive an ATMP under strictly 
controlled conditions in circumstances where there is no authorised 
medicinal product available. The interpretation of the so-called 
‘hospital exemption’ is causing confusion in member states and will 
be discussed below.
Not all of the manufacturing processes for ATMPs fall under the 
ATMP regulations when the ATMPs are produced from human tissues 
or cells. The 2004 European Union Human Tissues and Cells Directive 
(EUTCD)[43] provides quality and safety standards for human tissues 
and cells used for therapeutic purposes, and applies to all stages 
from donation to processing, storage and distribution. Implemented 
at a national level, it sets out the requirements for the accreditation, 
designation, authorisation, or licensing for the procurement and 
testing of the biological material intended for human applications.  
Table 1. (continued) Stem cell research: Regulatory approaches
Jurisdiction
*Legal position unclear, e.g. whether permitted 
or prohibited












of hESC lines 







hESCs, but permit 
importation of 
hESC lines
        Illinois √ √
        Iowa √ √
        Maryland √ √
        Massachusetts √ √
        Michigan √ √
        Montana √ √
        New Jersey √ √
        Oklahoma √ √
        Virginia √* √
A full list of legal references for the relevant laws and policies for each of the countries listed in this table can be obtained from the corresponding author (slabbmn@unisa.ac.za)
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Products containing human tissues or cells (viable or non-viable) 
cannot be classified as medical devices in the EU in terms of the 
Council Directive concerning medical devices,[44] despite containing 
elements of medical devices, unlike the position in the USA (see 
discussion below).
United States of America
(Table 3) The US Food and Drug Administration (FDA) is the regulatory 
authority responsible for the regulation of, among others, therapeutic 
products, which may include drugs, devices, biological or combination 
products (containing two or more different regulated components, 
e.g. drug and device or biologic and device). Regulations in the Code 
of Federal Regulations (CFR) pertaining to cell therapy products 
are the Investigational New Drugs (IND) regulations (21 CFR 312), 
biologics regulations (21 CFR 600), regulations on human cells, tissues 
and cellular and tissue-based products (HCT/P)s (regulations; 21 CFR 
1271), and current good manufacturing practice regulations (21 CFR 
211). The FDA’s HCT/P regulations create a tiered framework based on 
sections 351 and 361 of the Public Health Services Act (PHSA). HCT/
Ps, described as articles ‘containing or consisting of human cells or 
tissues that are intended for implantation, transplantation, infusion 
or transfer into a person’ (21 CFR 1271.3(d)), are subject to the HCT/
Ps regulations, unless removed from a patient and implanted into 
the same patient as part of the same surgical procedure (21 CFR 
1271.15(b)).[45]
Although subject to the HCT/Ps regulations, no licence is necessary 
for section 361 HTC/Ps that meet certain criteria, e.g. if minimally 
manipulated, intended for homologous use and not combined 
with any other product, and autologous, e.g. the patient is treated 
with his or her own cells (21 CFR 1271.10(a)). HCT/Ps not meeting 
these criteria, however, are also subject to the good tissue practice 
requirements[46] and will in addition be regulated as drugs, biologics 
or devices under section 351 of the PHSA (21 CFR 1271.20). Stem cell-
based therapies involving more than minimally manipulated cells 
will mostly fall within the last-mentioned category, even if used for 
autologous purposes. 
The meaning of ‘more than minimally manipulated’ was highlighted 
in the USA in a 2014 judgment. This case revolved around the FDA’s 
action against Regenerative Sciences, LLC, who manufactured a 
product called Regenexx™, consisting of autologous mesenchymal 
stem cells manipulated outside of the body and injected back into 
patients with orthopaedic injuries. The US Circuit Court of Appeals 
for the District of Columbia held that: (i) the cell mixture used for this 
procedure contained both a drug and biologic; (ii) it was more than 
minimally manipulated under section 351 of the PHSA; (iii) it qualified 
as interstate commerce; and (iv) was hence subject to the regulation 
and approval of the FDA.[47] 
In terms of the FDA framework, physicians may administer more 
than minimally manipulated stem cell products to patients in two 
ways. The first is permitted in accordance with the FDA’s programme 
for ‘expanded access to investigational drugs and biological products 
for treatment use’, better known as ‘compassionate use’, provided 
that the product in question is being tested in a present clinical trial 
and only if expanded access will not interfere with the conduct of 
clinical investigations.[48] Clinicians are allowed to charge patients to 
recover direct costs, as well as those administrative costs associated 
with expanded access use. The second exception is the ‘off-label 
prescribing’ of FDA-approved stem cell products, which refers to the 
prescribing of medicine in a manner that differs from the specified 
instructions.[49]
It is generally accepted in both the EU and USA that the deliberate 
expansion of cells in culture substitutes more than minimal 
manipulation. Manipulated autologous cells for structural use, on 
the other hand, fall within the ambit of somatic cell therapy products 
and require an ‘investigational new drug’ (IND) exemption or the FDA 
license approval. 
The FDA facilitates regulatory compliance through guidance 
documents via the Centre for Biologics Evaluation and Research (CBER). 
The FDA offers advisory committee meetings which may discuss 
pertinent questions relating to a particular product or product area. The 
Office of Cellular, Tissue and Gene Therapies’ (OCTGT) own committee, 
the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC), 
is tasked to discuss cell-therapy products. Various guidance documents 
provide clarity on specific regulatory issues. For example, HCT/Ps from 
adipose tissue[50] and minimally manipulated HCT/Ps[51] are the focus of 
recent FDA draft guidance documents.
Regulatory challenges
There is no doubt that stem cell-based therapies are developing very 
fast and that regulatory frameworks should be flexible enough to 
accommodate the pace of scientific progress. It is generally agreed 
that more research is necessary on the procedures to establish the 
safety and efficacy of stem cell products and the prediction of 
potential risks. Most regulatory models seem to follow a risk-based 
approach that focuses on both extrinsic issues (e.g. donor selection, 
sample procurement to limit risk of transmitting communicable 
diseases, and manufacturing and handling practices) and intrinsic 
issues (such as cell origin). Safety issues (following reports of serious 
adverse events) seem to receive more attention than efficacy issues. 
This makes the conventional pharmaceutical regulatory model an 
uncomfortable fit for the clinical translation of the cells into products. 
There is a need for the global harmonisation of guidelines covering 
a broad range of issues, which due to the limited scope of this article, 
cannot be discussed. Despite broadly similar regulatory requirements 
and procedures with regard to product pre-market approval 
processes (to establish safety, efficacy and quality), regulation of 
clinical trials using Good Clinical Practice (GCP) and regulation 
and licensing of manufacturing using Good Manufacturing Practice 
(GMP) (primarily the result of increased harmonisation of therapeutic 
product regulation under the auspices of the ICH of Technical 
Requirements for Registration of Pharmaceuticals for Human Use), 
specific disparities remain. Two examples are the issues of donor 
eligibility and the suitability of stem cell lines for use in clinical trials 
and subsequent commercialisation.[52] The legal regulation of human 
tissue (governing the procurement, use and disposal of human tissue) 
and tissue establishments across jurisdictions is also diverse, creating 
additional obstacles.
Harmonisation attempts are furthermore hampered by ambiguity 
and uncertainty with regard to the following issues:
Product classification
The scope of what constitutes cell-based products is unclear. The 
term ‘stem cell-based products’ refers to ‘products intended to be 
administered to a patient’, which ‘contain or are derived from stem 
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cells’.[53] These include three therapeutic 
concepts for the use of stem cells, namely 
direct administration, transplantation of 
differentiated stem cell progeny, and tissue 
engineering.[53] As far as direct administration 
is concerned, stem cells are introduced either 
locally or systemically into a patient’s body, after 
which the cells migrate to the intended site 
where differentiation into the appropriate cell 
type takes place.[53] With transplantation, the 
stem cells are first cultivated in vitro, followed 
by their differentiation into the desired tissue 
type, before being transplanted into the 
patient. In the case of tissue engineering, cells 
are seeded or implanted onto a scaffold or 
matrix, where the combination approximates 
the desired tissue.[53] Adding to the complexity 
is the fact that in any of these applications, 
cells from different sources may be used (as 
discussed earlier in this article), resulting 
in the eventual product being classified as 
either allogeneic (cells from a donor are used), 
autologous (recipient’s own cells are used), 
or xenogeneic (cells from another species 
are used).[53] The unique nature of these 
products means that methods and standards 
traditionally used with regard to conventional 
pharmaceutical products to ensure the safety, 
efficacy and quality of the stem cell-based 
products, may not be sufficient. Combination 
products are also addressed very differently 
across jurisdictions. Although products falling 
within two or more categories are normally 
assessed according to their principal or 
primary mode of action (PMOA), assessed on 
a case-by-case basis, this assessment cannot 
always be made with certainty and may lead to 
undesired results.[53] 
Product categories within the EU and the 
USA have their own challenges. In the EU, 
for example, ATMPs include three types of 
medicinal products, namely gene therapies, 
somatic cell therapies, and tissue engineered 
products. It is often difficult to determine 
to which of these categories a product 
belongs. Another controversial assessment 
is the question of whether manipulation of 
a living material is minimal or substantial. 
Moreover, some of the new biological 
products could easily fit one or more of 
the categories of medicines, medical devices, 
cosmetics, or tissues and cells. Regulatory 
discrepancies in this regard may mean that 
one product may be subject to different 
requirements across the EU. These disparities 
will negatively impact on incentives to 
develop ATMPs by discouraging investments, 
distorting competition between developers 
and impeding the free movement of these 
products.[54]
‘Minimally manipulated v. ‘substantially 
manipulated’ 
The interpretation of ‘minimally manipulated’ 
stem cells is important for various reasons. 





Regulation (EC) No. 1394/2007 Of the European Parliament and of the Council on ATMPs
Regulation (EU) No. 536/2014 Of the European Parliament and of the Council on clinical 
trials on medicinal products for human use, repealing 
Directive 2001/20/EC
Directive 2004/23/EC EUTCD, which establishes the standard quality, donation 
safety, harvesting, tests, processing, preservation, storage, 
and distribution of human tissues and cells
Directive 2006/17/EC Implementing Directive 2004/23/EC of the European 
Parliament and of the Council as regards certain technical 
requirements for the donation, procurement and testing of 
human tissues and cells
Directive 2003/94/EC Good manufacturing practice for medicinal products for 




Medicinal products for human use (includes 2003/63/EC, 
2004/27/EC
and advanced therapy regulation). 
Commission Directive 2009/120/EC amending Directive 
2001/83/EC of the European Parliament and of the Council 
on the community code relating to medicinal products for 
human use as regards ATMPs.








Public Health Service Act, sections 351 and 361 [42 USC 264]
Regulations for Investigational New Drugs (IND), Code of Federal 
Regulations, Part 312
21 CFR 1271* Human Cells, tissue, cellular- and tissue-based products
21 CFR 210 Current good manufacturing practice in manufacturing,
processing, packaging or holding of drugs
21 CFR 211 Current good manufacturing practice for finished
pharmaceuticals 
21 CFR 600
21 CFR 610 
Description of general safety and sterility tests administered by
parenteral routes (note, this is not a safety test of the product itself ).
21 CFR 314
21 CFF 312
Adequate and well-controlled clinical trials
21 CFR 50
21 CFR 56
Subpart B. Informed consent of human subjects
21 CFR 58 Good laboratory practices for nonclinical laboratory studies
*For tissues and cells procured after 25 May 2005
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Most significantly, if the stem cells were more than minimally 
manipulated, the product is legally destined for the more stringent 
and expensive ‘drug pathway’ for broad clinical use, which includes, for 
example, the controlling of the resulting products through mandated 
premarket testing for safety and efficacy in specified indications and 
the conducting of a series of registered multiphase (I-III) clinical trials. 
The Regenexx™ case, referred to above, prompted the publication of 
guidelines by the FDA in December 2014 on minimally manipulated 
cells.[55] For example, manipulations with adipose tissue (e.g. isolating 
cells from adipose tissue) will in future be considered to be more than 
minimally manipulated, as this changes the original characteristics of 
the cells.[55] These guidelines will be instructive for other jurisdictions 
where the regulatory framework for stem cell-based therapies is 
immature or silent on a range of issues relating to the regulation of 
cell based therapies.
Treatments or products exempted from product regulation
The legal regulation of stem cell treatments, which are exempted from 
product regulation, is likewise inconsistent across jurisdictions. Products 
assessed as having minimal risks and not posing serious safety concerns 
are normally subject to limited regulatory oversight. Autologous cells 
that: (i) have not been manipulated extensively or combined with other 
articles; (ii) are intended for homologous use in functionally compatible 
tissues, and/or (iii) are harvested and transplanted as part of the same 
surgical procedure, are generally exempted from product regulation, 
such as hematopoietic stem cell transplants aimed at restoring 
bone marrow function.[56] In this regard, different interpretations 
exist regarding the level of manipulation (e.g. the exact meaning of 
‘minimally’ or ‘more than minimally manipulated’) and the intended use 
of the cells across jurisdictions, as well as definitions used to describe 
these processes. Concepts such as ‘homologous’ or ‘non-substantial’ are 
likewise not always clearly defined, leading to diverse assessments of 
which cells are classified as posing a ‘minimal risk’ and those requiring 
more stringent regulation.[56] 
This uncertainty also extends to more than minimally manipulated 
cell-based products, regulated as drugs in exceptional instances 
where patients are provided with access to medicinal products 
lacking the relevant evidence required for market licensing. These 
exemptions are regulated differently across jurisdictions and under 
different descriptions, such as ‘compassionate use’ or ‘special access’ 
provisions (e.g. in the USA). These exceptions fall within the scope 
of the regulation of medical practice, often with additional oversight 
mechanisms, such as approval from an institutional review board, 
or as is the case in the EU, under the so-called ‘hospital exemption’, 
referred to above. The scope of the ‘hospital exemption’ is also not 
clearly and uniformly understood in the different member states and 
related terms, such as ‘prepared on a non-routine basis’, referred to in 
the discussion on the EU above, are equally obscure.[57]
The legal uncertainty in this context is underscored by a 2014 decision 
of the European Court of Human Rights in Durisotto v. Italy.[58] This case 
concerns a patient’s appeal to a ruling of an Italian court that denied the 
patient access to an unproven stem cell treatment, based on an alleged 
infringement of several articles of the European Convention of Human 
Rights. The judgment made it clear that patients do not have an 
automatic right (on compassionate grounds) to a stem cell treatment 
that lacks evidence of efficacy. Mr Nivio Durisotto, whose daughter 
(the patient) suffers from a degenerative brain disease, insisted that 
his daughter was entitled to receive a controversial stem cell treatment 
offered by the Stamina Foundation. Dismissing Mr Durisotto’s claim, 
the court stated that the Italian ruling rightly pursued the legitimate 
aim of protecting health and that the ruling was proportionate to this 
aim. Despite the emphasis on demonstrated efficacy, the court did 
not distinguish between compassionate treatments and unproven 
therapies, except to confirm that unproven therapies may not be used 
for compassionate purposes.  
The increase in unsafe individualised treatments or experimental 
treatments offered to patients outside of the scope of a medicines 
regulatory framework demonstrates that, once again, clarity is 
required, as the laws and regulations governing medical practice and 
the conduct of healthcare professionals may not always be sufficient 
to address these issues.
Conclusion
This paper is premised on the assumption that a comparative 
understanding of the global regulatory framework with regard to 
stem cell research and therapy will assist in formulating more effective, 
better harmonised and ethical legal responses to a very complex and 
rapidly evolving scientific field. The paper first considered a few issues 
that raise specific ethical concerns, which include, among others, 
moral perceptions regarding the human embryo, reproductive and 
therapeutic cloning, oocyte donation, intellectual property rights 
in tissues and cells and issues relating to privacy, confidentiality and 
informed consent.
A comparative overview focusing on 35 selected jurisdictions was 
undertaken next, using as a yardstick for comparison the permissibility 
or prohibition of specific stem cell research activities in these countries 
including the creation of human embryos through processes such as 
IVF and SCNT and the resulting derivation of hESC lines. A distinction 
was drawn between so-called liberal and permissive regulatory 
regimens (e.g. those that permit embryo research and the derivation 
of hECS from various sources and technologies, such as IVF and SCNT); 
moderate regimens that follow a regulatory compromise (e.g. those 
that may permit research using excess IVF embryos, but prohibit 
hESC derivation from other sources); and finally, those restrictive 
jurisdictions that prohibit embryo research and related activities (e.g. 
the use of excess IVF embryos in hESC research and the derivation 
of hESC lines). This comparative overview illustrates that issues on 
which legal and policy variance is the most divergent are the moral 
and legal status of the human embryo and the patenting of human 
tissues, whereas consensus appears more evident with regard to the 
prohibition of reproductive cloning. In addition, it emerges that the 
transnational sharing of stem cell lines and data across jurisdictions 
will depend on the success with which jurisdictions succeed in 
harmonising laws and policies in key areas, most notably those 
relating to research oversight, technical standards, quality assurance 
and operating procedures.
The discussion on the legal regulation of stem cell-based products 
reveals very specific and unique challenges that make the traditional 
pharmaceutical regulatory model a poor fit for the clinical translation 
of stem cells. Firstly, issues revolving around product classification 
need to be clarified, as novel stem cell products may exhibit complex 
characteristics that could belong to more than one of the existing 
product classifications (e.g. medicines and medical devices). Clear, 
flexible and predictable guidelines and definitions are necessary to 
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deal with these overlapping, combination or borderline products, 
considering the likelihood the new product types may defy existing 
product classifications. Secondly, the position with regard to 
the regulation of novel and individualised stem cell products or 
treatments should also be more transparent, particularly in view 
of the proliferation of unsafe or potentially harmful experimental 
treatments offered to vulnerable patients, which generally fall 
outside of the scope of the regulation of medicines. The recent 
judgment of the European Court of Human Rights concerning a 
patient’s claim to have access to an unproven experimental stem cell 
treatment demonstrates how unsettled the current legal regulatory 
framework relating to stem cell therapies is, not to mention the need 
to strike a balance between patient expectations and entitlements 
with regard to unproven treatments and the broader objective of 
the protection of vulnerable patients from unsafe and potentially 
harmful treatments. The regulation of these exemptions should not 
be exploited, particularly if there is no reasonable justification for 
subjecting the patient to serious unforeseen risks. Thirdly, different 
understandings of key concepts in the regulatory context, such as 
‘minimally manipulated’ cells or cells ‘prepared on a non-routine 
basis’ provide another obstacle.
The swiftly evolving field of stem cell research and therapy will 
continue to place high demands on regulators and policymakers to 
provide clear and unambiguous, yet flexible rules and guidelines. 
A balance will need to be achieved between governing stem cell 
research and not impeding its clinical translation. There is no doubt 
that collaborative efforts, some of which are referred to in this paper, 
will yield the most promising results in providing harmonised solutions 
to some of the legal lacunae and ambiguities referred to herein. 
Considered a permissive legal system as far as stem cell research is 
concerned, South Africa specifically needs to take cognisance of the 
lessons and shared best practices emanating from the global domain.
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